Background: The
apolipoprotein E (APOE, gene; apoE,
protein) ε4 allele is the most commonly
identified genetic risk factor for typical late-onset sporadic Alzheimer’s
disease (AD). Each APOEε4 allele roughly triples the relative
risk for AD compared to that of the reference allele, APOEε3. Methods:We have employed hyperspectral fluorescence
imaging with an amyloid-specific, conformation-sensing probe, p-FTAA, to
elucidate protein aggregate structure and morphology in fresh frozen prefrontal
cortex samples from human postmortem AD brain tissue samples from patients
homozygous for either APOEε3 or APOEε4. Results: As expected APOEε4/ε4 tissues had a significantly larger load of CAA than APOEε3/ε3. APOE isoform-dependent morphological differences in amyloid plaques were also
observed. Amyloid plaques in APOEε3/ε3
tissue had small spherical cores and large coronas while amyloid plaques in APOEε4/ε4 tissues had large irregular and
multi-lobulated plaques with relatively smaller coronas. Despite the different
morphologies of their cores, the p-FTAA stained APOEε3/ε3 amyloid plaque cores had spectral
properties identical to those of APOEε4/ε4
plaque cores. Conclusions: These data support the hypothesis that one
mechanism by which the APOEε4 allele affects AD is by modulating
the macrostructure of pathological protein deposits in the brain. APOEε4
is associated with a higher density of amyloid plaques (as compared to APOEε3).We speculate that multilobulated APOE ε4-associated plaques
arise from multiple initiation foci that coalesce as the plaques grow.
References
[1]
Gandy, S. and DeKosky, S.T. (2013) Toward the Treatment and Prevention of Alzheimer’s Disease: Rational Strategies and Recent Progress. Annual Review of Medicine, 64, 367-383. https://doi.org/10.1146/annurev-med-092611-084441
[2]
Gandy, S. and DeKosky, S.T. (2013) 2012: The Year in Dementia. The Lancet Neurology, 12, 4-6. https://doi.org/10.1016/S1474-4422(12)70284-3
[3]
Lublin, A.L. and Gandy, S. (2010) Amyloid-beta Oligomers: Possible Roles as Key Neurotoxins in Alzheimer’s Disease. Mount Sinai Journal of Medicine, 77, 43-49.
https://doi.org/10.1002/msj.20160
[4]
Gandy, S., Simon, A.J., Steele, J.W., Lublin, A.L., Lah, J.J., Walker, L.C., et al. (2010) Days to Criterion as an Indicator of Toxicity Associated with Human Alzheimer Amyloid-beta Oligomers. Annals of Neurology, 68, 220-230.
https://doi.org/10.1002/ana.22052
[5]
Hyman, B.T., West, H.L., Rebeck, G.W., Buldyrev, S.V., Mantegna, R.N., Ukleja, M., Havlin, S. and Stanley, H.E. (1995) Quantitative Analysis of Senile Plaques in Alzheimer Disease: Observation of Log-Normal Size Distribution and Molecular Epidemiology of Differences Associated with Apolipoprotein E Genotype and Trisomy 21 (Down Syndrome). Proceedings of the National Academy of Sciences of the United States of America, 92, 3586-3590. https://doi.org/10.1073/pnas.92.8.3586
[6]
Rebeck, G.W., Reiter, J.S., Strickland, D.K. and Hyman, B.T. (1993) Apolipoprotein E in Sporadic Alzheimer’s Disease: Allelic Variation and Receptor Interactions. Neuron, 11, 575-580. https://doi.org/10.1016/0896-6273(93)90070-8
[7]
Morris, J.C., et al. (2010) APOE Predicts Amyloid-beta but Not Tau Alzheimer Pathology in Cognitively Normal Aging. Annals of Neurology, 67, 122-131.
https://doi.org/10.1002/ana.21843
[8]
Holtzman, D.M., et al. (2000) Apolipoprotein E Isoform-Dependent Amyloid Deposition and Neuritic Degeneration in a Mouse Model of Alzheimer’s Disease. Proceedings of the National Academy of Sciences of the United States of America, 97, 2892-2897. https://doi.org/10.1073/pnas.050004797
[9]
Strittmatter, W.J., et al. (1993) Binding of Human Apolipoprotein E to Synthetic Amyloid beta Peptide: Isoform-Specific Effects and Implications for Late-Onset Alzheimer Disease. Proceedings of the National Academy of Sciences of the United States of America, 90, 8098-8102. https://doi.org/10.1073/pnas.90.17.8098
[10]
Castellano, J.M., et al. (2011) Human apoE Isoforms Differentially Regulate Brain Amyloid-beta Peptide Clearance. Science Translational Medicine, 3, 89ra57.
[11]
Näslund, J., Thyberg, J., Tjernberg, L.O., Wernstedt, C., Karlström, A.R., Bogdanovic, N., Gandy, S.E., Lannfelt, L., Terenius, L. and Nordstedt, C. (1995) Characterization of Stable Complexes Involving Apolipoprotein E and the Amyloid beta Peptide in Alzheimer’s Disease Brain. Neuron, 15, 219-228.
https://doi.org/10.1016/0896-6273(95)90079-9
[12]
Koffie, R.M., et al. (2012) Apolipoprotein E4 Effects in Alzheimer’s Disease Are Mediated by Synaptotoxic Oligomeric Amyloid-beta. Brain: A Journal of Neurology, 135, 2155-2168. https://doi.org/10.1093/brain/aws127
[13]
Sigurdson, C.J., et al. (2007) Prion Strain Discrimination Using Luminescent Conjugated Polymers. Nature Methods, 4, 1023-1030.
https://doi.org/10.1038/nmeth1131
[14]
Nilsson, K.P.R., Herland, A., Hammarström, P. and Inganas, O. (2005) Conjugated Polyelectrolytes: Conformation-Sensitive Optical Probes for Detection of Amyloid Fibril Formation. Biochemistry, 44, 3718-3724. https://doi.org/10.1021/bi047402u
[15]
Nilsson, K.P.R., et al. (2007) Imaging Distinct Conformational States of Amyloid-beta Fibrils in Alzheimer’s Disease Using Novel Luminescent Probes. ACS Chemical Biology, 2, 553-560. https://doi.org/10.1021/cb700116u
[16]
Åslund, A., et al. (2009) Novel Pentameric Thiophene Derivatives for in Vitro and in Vivo Optical Imaging of a Plethora of Protein Aggregates in Cerebral Amyloidoses. ACS Chemical Biology, 4, 673-684. https://doi.org/10.1021/cb900112v
[17]
Berg, I., Nilsson, K.P.R., Thor, S. and Hammarström, P. (2010) Efficient Imaging of Amyloid Deposits in Drosophila Models of Human Amyloidoses. Nature Protocols, 5, 935-944. https://doi.org/10.1038/nprot.2010.41
[18]
Klingstedt, T., et al. (2011) Synthesis of a Library of Oligothiophenes and Their Utilization as Fluorescent Ligands for Spectral Assignment of Protein Aggregates. Organic and Biomolecular Chemistry, 9, 8356-8370.
https://doi.org/10.1039/c1ob05637a
[19]
Caesar, I., Jonson, M., Nilsson, K.P.R., Thor, S. and Hammarström, P. (2012) Curcumin Promotes A-beta Fibrillation and Reduces Neurotoxicity in Transgenic Drosophila. PLOS ONE, 7, e31424. https://doi.org/10.1371/journal.pone.0031424
[20]
Nilsson, K.P., Joshi-Barr, S., Winson, O. and Sigurdson, C.J. (2010) Prion Strain Interactions Are Highly Selective. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30, 12094-12102.
https://doi.org/10.1523/JNEUROSCI.2417-10.2010
[21]
Hammarstrom, P., et al. (2010) A Fluorescent Pentameric Thiophene Derivative Detects in Vitro-Formed Prefibrillar Protein Aggregates. Biochemistry, 49, 6838-6845. https://doi.org/10.1021/bi100922r
[22]
Åslund, A., Nilsson, K.P.R. and Konradsson, P. (2009) Fluorescent Oligo and Poly-Thiophenes and Their Utilization for Recording Biological Events of Diverse Origin-When Organic Chemistry Meets Biology. Journal of Chemical Biology, 2, 161-175. https://doi.org/10.1007/s12154-009-0024-8
[23]
Rasmussen, J., et al. (2017) Amyloid Polymorphisms Constitute Distinct Clouds of Conformational Variants in Different Etiological Subtypes of Alzheimer’s Disease. Proceedings of the National Academy of Sciences of the United States of America, 114, 13018-13023. https://doi.org/10.1073/pnas.1713215114
[24]
Liu, H., et al. (2021) Distinct Conformers of Amyloid beta Accumulate in the Neocortex of Patients with Rapidly Progressive Alzheimer’s Disease. Journal of Biological Chemistry, 297, Article ID: 101267. https://doi.org/10.1016/j.jbc.2021.101267
[25]
Klingstedt, T. and Nilsson, K.P. (2011) Conjugated Polymers for Enhanced Bioimaging. Biochimica et Biophysica Acta, 1810, 286-296.
https://doi.org/10.1016/j.bbagen.2010.05.003
[26]
Dickson, T.C. and Vickers, J.C. (2001) The Morphological Phenotype of beta-Amyloid Plaques and Associated Neuritic Changes in Alzheimer’s Disease. Neuroscience, 105, 99-107. https://doi.org/10.1016/S0306-4522(01)00169-5
[27]
Raulin, A.C., Doss, S.V., Trottier, Z.A., Ikezu, T.C., Bu, G. and Liu, C.C. (2022) ApoE in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies. Molecular Neurodegeneration, 17, Article No. 72.
https://doi.org/10.1186/s13024-022-00574-4
[28]
Fändrich, M., Nyström, S., Nilsson, K.P.R., Böckmann, A., LeVine, H. and Hammarström, P. (2018) Amyloid Fibril Polymorphism: A Challenge for Molecular Imaging and Therapy. Journal of Internal Medicine, 283, 218-237.
https://doi.org/10.1111/joim.12732